摘要
他达拉非是新型的5型磷酸二酯酶(PDE5)抑制剂,口服用于治疗勃起功能障碍(ED)。在具有卓越的36h疗效的同时,他达拉非治疗ED的安全性和耐受性均十分良好,不良事件多为一过性的轻、中度事件。ED患者往往伴发多种基础疾病或同时需服用多种药物,因此,详细地了解他达拉非在一般人群以及某些特殊的高危人群中的安全性是十分重要的,本文就这方面内容进行了综述。
As a novel phosphodiesterase type 5 (PDES) inhibitor, tadalafil is administered orally for the treatment of erectile dysfunction (ED). In addition to its outstanding efficacy that lasts 36 hours, tadalafil shows an excellent safety and tolerance, with only a few transient mild to moderate adverse events. Usually ED patients are concomitantly afflicted with multiple pre-existing medical conditions or receive a range of drugs at the same time. Therefore, it is essential to understand its safety in general population and some special high-risk cohorts.
出处
《中华男科学杂志》
CAS
CSCD
北大核心
2009年第1期92-95,共4页
National Journal of Andrology